nach oben

Erschienen in:

17.05.2024 | Research

In vitro results with minimal blood toxicity of a combretastatin A4 analogue

verfasst von: Camila Chagas, Jaqueline Vital Mansano, Emerson Barbosa da Silva, Giuliana Petri, Beatriz da Costa Aguiar Alves Reis, Maria Lúcia Schumacher, Paula Silvia Haddad, Edimar Cristiano Pereira, Tatiane Nassar Britos, Eliezer J. Barreiro, Lídia Moreira Lima, Fabio Furlan Ferreira, Fernando Luiz Affonso Fonseca

Erschienen in: Investigational New Drugs | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Cancer is a disease caused by uncontrolled cell growth that is responsible for several deaths worldwide. Breast cancer is the most common type of cancer among women and is the leading cause of death. Chemotherapy is the most commonly used treatment for cancer; however, it often causes various side effects in patients. In this study, we evaluate the antineoplastic activity of a parent compound based on a combretastatin A4 analogue. We test the compound at 0.01 mg mL^− 1, 0.1 mg mL^− 1, 1.0 mg mL^− 1, 10.0 mg mL^− 1, 100.0 mg mL^− 1, and 1,000.0 mg mL^− 1. To assess molecular antineoplastic activity, we conduct in vitro tests to determine the viability of Ehrlich cells and the blood mononuclear fraction. We also analyze the cytotoxic behavior of the compound in the blood and blood smear. The results show that the molecule has a promising antineoplastic effect and crucial anticarcinogenic action. The toxicity of blood cells does not show statistically significant changes.

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA: A Cancer. J Clin 73:17–48. https://doi.org/10.3322/caac.21763CrossRef

Cancer - PAHO/WHO| Pan American Health Organization https://www.paho.org/en/topics/cancer. Accessed 27 Dec 2023

Cancer https://www.who.int/health-topics/cancer. Accessed 27 Dec 2023

Santos MDO, Lima FCDSD, Martins LFL et al (2023) Estimativa De Incidência De Câncer no Brasil, 2023–2025. https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700. Rev Bras Cancerol 69:

Wendt C, Margolin S (2019) Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol 58:135–146. https://doi.org/10.1080/0284186x.2018.1529428CrossRefPubMed

PDQ Adult Treatment Editorial Board (2002) Breast Cancer Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. National Cancer Institute (US). Bethesda (MD)

Debela DT, Muzazu SG, Heraro KD et al (2021) New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med 9:20503121211034366. https://doi.org/10.1177/20503121211034366CrossRefPubMedPubMedCentral

Pantziarka P, Capistrano IR, De Potter A et al (2021) An Open Access Database of Licensed Cancer drugs. Front Pharmacol 12:627574. https://doi.org/10.3389/fphar.2021.627574CrossRefPubMedPubMedCentral

Anticancerfund (ed) (2021) https://www.anticancerfund.org/en/cancerdrugs-db. Accessed 27 Dec 2023

10.

Chow LWC, Biganzoli L, Leo AD et al (2017) Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and caucasian breast cancer patients. Asia Pac J Clin Oncol 13:372–378. https://doi.org/10.1111/ajco.12682CrossRefPubMed

11.

Kim S, Kang SI, Kim S, Kim JH (2021) Prognostic implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer. J Surg Res 267:391–396. https://doi.org/10.1016/j.jss.2021.05.002CrossRefPubMed

12.

Tao G, Huang J, Moorthy B et al (2020) Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol 16:1109–1124. https://doi.org/10.1080/17425255.2020.1815705CrossRefPubMedPubMedCentral

13.

Akbarali HI, Muchhala KH, Jessup DK, Cheatham S (2022) Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res 155:131–166. https://doi.org/10.1016/bs.acr.2022.02.007CrossRefPubMedPubMedCentral

14.

da Silva EB, Chagas CS, Oliveira MPA et al (2019) Comparative study on myelotoxic and antineoplastic action of Synadenium umbellatum, Vitis vinifera and Resveratrol. J Nat Remedies 80–86. https://doi.org/10.18311/jnr/2019/23383

15.

Safwat MA, Kandil BA, Elblbesy MA et al (2020) Epigallocatechin-3-gallate-loaded Gold nanoparticles: Preparation and evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing mice. Pharmaceuticals (Basel) 13:254. https://doi.org/10.3390/ph13090254CrossRefPubMed

16.

Brito WAS, Freund E, Nascimento TDH do, et al (2021) The Anticancer efficacy of plasma-oxidized saline (POS) in the Ehrlich Ascites Carcinoma Model in Vitro and in vivo. Biomedicines 9:932. https://doi.org/10.3390/biomedicines9080932CrossRefPubMedPubMedCentral

17.

Fernandes PD, Guerra FS, Sales NM et al (2015) Characterization of the inflammatory response during Ehrlich ascitic tumor development. J Pharmacol Toxicol Methods 71:83–89. https://doi.org/10.1016/j.vascn.2014.09.001CrossRefPubMed

18.

Ozaslan M, Karagoz ID, Kilic IH, Guldur ME (2011) Ehrlich ascites carcinoma. Afr J Biotechnol 10:2375–2378. https://doi.org/10.4314/ajb.v10i13CrossRef

19.

Nik ME, Momtazi-Borojeni AA, Zamani P et al (2019) Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment. J Cell Physiol 234:14721–14733. https://doi.org/10.1002/jcp.28230CrossRefPubMed

20.

Paidakula S, Nerella S, Kankala S, Kankala RK (2022) Recent trends in tubulin-binding combretastatin A-4 analogs for Anticancer Drug Development. Curr Med Chem 29:3748–3773. https://doi.org/10.2174/0929867328666211202101641CrossRefPubMed

21.

Chen Z-H, Xu R-M, Zheng G-H et al (2023) Development of Combretastatin A-4 Analogues as potential Anticancer agents with Improved Aqueous solubility. Molecules 28:1717. https://doi.org/10.3390/molecules28041717CrossRefPubMedPubMedCentral

22.

de Figueiredo LP, Ibiapino AL, Amaral DN, do et al (2017) Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. J Mol Struct 1147:226–234. https://doi.org/10.1016/j.molstruc.2017.06.093CrossRef

23.

do Amaral DN, Cavalcanti BC, Bezerra DP et al (2014) Docking, synthesis and antiproliferative activity of N-Acylhydrazone derivatives designed as Combretastatin A4 analogues. PLoS ONE 9:e85380. https://doi.org/10.1371/journal.pone.0085380CrossRefPubMedPubMedCentral

24.

Silva JC, Júnior RG, de O, Silva MG e, et al (2018) LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice. PLoS ONE 13:e0199009. https://doi.org/10.1371/journal.pone.0199009CrossRefPubMedPubMedCentral

25.

Karatoprak GŞ, Küpeli Akkol E, Genç Y et al (2020) Combretastatins: an overview of structure, probable mechanisms of action and potential applications. Molecules 25:2560. https://doi.org/10.3390/molecules25112560CrossRefPubMedPubMedCentral

26.

Sherbet GV (2020) Combretastatin analogues in cancer biology: a prospective view. J Cell Biochem 121:2127–2138. https://doi.org/10.1002/jcb.29342CrossRefPubMed

27.

Shahrasbi A, Armin A, Ardebili A et al (2017) Hematologic adverse effects following systemic chemotherapy. 2:1–3. https://doi.org/10.4172/2576-3857.1000110

28.

de Oliveira Gozzo T, Nascimento TG, do, Panobianco MS, de Almeida AM (2011) Ocurrencia de neutropenia en mujeres con cáncer de mama durante El Tratamiento quimioterápico. Acta Paulista De Enfermagem 24:810–814. https://doi.org/10.1590/s0103-21002011000600014CrossRef

29.

Niraj J, Färkkilä A, D’Andrea AD (2019) The Fanconi Anemia Pathway in Cancer. Annu Rev Cancer Biol 3:457–478. https://doi.org/10.1146/annurev-cancerbio-030617-050422CrossRefPubMed

30.

Gilreath JA, Rodgers GM (2020) How I treat cancer-associated anemia. Blood 136:801–813. https://doi.org/10.1182/blood.2019004017CrossRefPubMed

31.

Abiri B, Vafa M (2020) Iron Deficiency and Anemia in Cancer patients: the role of Iron Treatment in Anemic Cancer patients. Nutr Cancer 72:864–872. https://doi.org/10.1080/01635581.2019.1658794CrossRefPubMed

32.

Wang Y-J, Fletcher R, Yu J, Zhang L (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194–203. https://doi.org/10.1016/j.gendis.2018.05.003CrossRefPubMedPubMedCentral

33.

Shrivastava S, Swati Shrivastava, Singh N et al (2016) Comparative study of hematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer. Int J Res Med Sci 5:311–315. https://doi.org/10.18203/2320-6012.ijrms20164569CrossRef

34.

Coiffier B, Guastalla J-P, Pujade-Lauraine E et al (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37:1617–1623. https://doi.org/10.1016/s0959-8049(01)00169-1CrossRefPubMed

35.

Shitara K, Matsuo K, Oze I et al (2011) Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol 68:301–307. https://doi.org/10.1007/s00280-010-1487-6CrossRefPubMed

36.

Jinna S, Khandhar PB (2023) Thrombocytopenia. In: StatPearls. StatPearls Publishing, Treasure Island (FL)

37.

Kuter DJ (2022) Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica 107:1243–1263. https://doi.org/10.3324/haematol.2021.279512CrossRefPubMedPubMedCentral

38.

Brasileiro LDA, Oliveira JMD, Castilho SRD (2021) Incidência E manejo da neutropenia em pacientes submetidas Ao Protocolo AC-T no tratamento adjuvante de câncer de mama. RSD 10:e48310616023. https://doi.org/10.33448/rsd-v10i6.16018CrossRef

39.

Schirrmacher V (2019) From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review). Int J Oncol 54:407–419. https://doi.org/10.3892/ijo.2018.4661CrossRefPubMed

40.

Barbosa G, Gelves LGV, Costa CMX et al (2022) Discovery of putative dual inhibitor of tubulin and EGFR by phenotypic Approach on LASSBio-1586 homologs. Pharmaceuticals (Basel) 15:913. https://doi.org/10.3390/ph15080913CrossRefPubMed

Titel: In vitro results with minimal blood toxicity of a combretastatin A4 analogue
verfasst von: Camila Chagas
Jaqueline Vital Mansano
Emerson Barbosa da Silva
Giuliana Petri
Beatriz da Costa Aguiar Alves Reis
Maria Lúcia Schumacher
Paula Silvia Haddad
Edimar Cristiano Pereira
Tatiane Nassar Britos
Eliezer J. Barreiro
Lídia Moreira Lima
Fabio Furlan Ferreira
Fernando Luiz Affonso Fonseca
Publikationsdatum: 17.05.2024
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 3/2024
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-024-01440-4

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

Open Access
Research

Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia

Open Access
Research

Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance

Brief Report

The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells

Research

The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer

Open Access
Research

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Open Access
Correction

Neu im Fachgebiet Onkologie

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

17.04.2025
Koloskopie
Nachrichten

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Wenn die Krebstherapie die Identität verändert

17.04.2025
Nebenwirkungen der Krebstherapie
Nachrichten

Tumortherapien können die Fingerbeere so verändern, dass eine Fingerabdruck-abhängige Identitätskontrolle fehlschlägt. Dafür sprechen zumindest Daten aus der Literatur, die Forschende nun erstmals für ein Review zusammengetragen haben. Vieles ist im Moment aber noch unklar.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

In vitro results with minimal blood toxicity of a combretastatin A4 analogue

Abstract

Weitere Artikel der Ausgabe 3/2024

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia

Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance

The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells

The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Neu im Fachgebiet Onkologie

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wenn die Krebstherapie die Identität verändert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten